Status:
TERMINATED
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Anemia
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Body weight \>/= 99lbs
- ECOG 0-2
- Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
- Screening hemoglobin level of \</= 11.0 g/dL for men or \</= 10.0 for women
Exclusion
- History of or concurrent second malignancy
- Evidence of primary or metastatic malignancy involving the Central Nervous System
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00083434
Start Date
February 1 2004
End Date
October 1 2004
Last Update
April 27 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Urology Medical Center
Anaheim, California, United States, 92801
2
Shapiro, Stafford & Yee
Arcadia, California, United States, 91007
3
California Cancer Center
Fresno, California, United States, 93720
4
Tukoi Research
North Miami, Florida, United States, 33161